Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

The Ademi Firm is investigating scPharmaceuticals (NASDAQ: SCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with MannKind.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Shareholders of scPharmaceuticals will receive $5.35 per share in cash plus contingent value rights worth up to $1.00 per share. scPharmaceuticals insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for scPharmaceuticals by imposing a significant penalty if scPharmaceuticals accepts a competing bid. We are investigating the conduct of the scPharmaceuticals board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825132116/en/